An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.

Owing to the propensity for visual loss, immunosuppressive treatment in the form of systemic and/or local therapy is often required for the management of noninfective intermediate and posterior ...

Please provide your email address to receive an email when new articles are posted on . Individually tailored immunosuppressive therapy may help preserve vision in at least one eye in children with ...

An estimated five to ten percent of blindness worldwide is due to the rare inflammatory eye disease uveitis. Intermediate uveitis is often associated with a chronic course of the disease and the need ...

Vitreous cysts are rare structural entities that have been reported sporadically in the literature. Several associations have been described, including retinitis pigmentosa, Toxoplasmosis, trauma, ...

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that ...

Q. I’m 64 and have been diagnosed with uveitis in my right eye. What causes it, and what’s the best treatment? A. Uveitis is inflammation of one or more of the parts of the uvea, the layer of tissue ...

Expert Rev Ophthalmol. 2012;7(6):587-594. Multiple sclerosis (MS) is a neurodegenerative disease that causes demyelination of the CNS. MS can cause a wide variety of neuro-ophthalmic manifestations ...

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that ...